<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753050</url>
  </required_header>
  <id_info>
    <org_study_id>HipHop</org_study_id>
    <secondary_id>EA1/315/12</secondary_id>
    <nct_id>NCT01753050</nct_id>
  </id_info>
  <brief_title>HIP Surgery - Hemodynamic Optimization Project</brief_title>
  <acronym>HipHop</acronym>
  <official_title>A Quality Improvement Project for Goal-directed Intraoperative Hemodynamic Optimization in Patients Redo Hip Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have demonstrated that goal-directed fluid therapy during high- risk-surgery
      reduces morbidity and length of hospital stay. This quality improvement is design to evaluate
      the implementation of an intraoperative goal-directed therapy, using a pulse contour analysis
      monitor to optimize the stroke volume, in patients undergoing redo-hip-surgery. The primary
      combined endpoints will be the incidence of postoperative complications and the secondary
      endpoints will be the decrease of hospital length of stay, length of ICU stay and hospital
      postoperative mortality. We amended another 130 patients getting crystalloid fluids in the
      hemodynamic optimization protocol.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>30days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital and ICU stay</measure>
    <time_frame>30days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Redo Hip Surgery</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No specific hemodynamic optimization measures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodynamic optimization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodynamic optimization by stroke volume monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stroke volume monitoring</intervention_name>
    <description>Pulse contour stroke volume monitoring</description>
    <arm_group_label>Hemodynamic optimization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing redo hip surgery

          -  age above 18 years

          -  signed informed consent

        Exclusion Criteria:

          -  urgent or emergency surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sascha Treskatsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Operative Intensive Care Medicine, CCM and CVK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine Campus Charit√© Mitte / Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Sascha Treskatsch</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

